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Abstract
Background and Aims: Hepatitis C virus (HCV) cirrhosis is
the leading indication for liver transplantation in the United
States and recurrent HCV following liver transplantation is
a major cause of allograft loss and mortality. Liver biopsies
are commonly used to identify recurrent HCV and determine
the need for antiviral therapy. The introduction of direct-
acting antiviral agents (DAAs) has changed the management
of recurrent HCV infection. This study aimed to describe the
role of liver biopsies in liver transplant recipients with
HCV after the introduction of DAAs.Methods: A retrospective
analysis was performed looking at the rate of liver biopsies
post-liver transplantation for HCV. The analysis included 475
adult liver transplants for hepatitis C performed at the Univer-
sity of California, Los Angeles from January 1, 2006 to Octo-
ber 1, 2015. Patients were divided into two eras, pre- and
post-introduction of DAAs on December 1, 2013. Results:
In the era before the introduction of DAAs, the percentage
of patients biopsied was significantly higher compared to
the era after the introduction of DAAs (56.1% vs. 26.9%,
p < 0.001). Conclusion: The introduction of DAAs has
changed the management of liver biopsy following liver trans-
plantation and the management of recurrent HCV. Given that
DAAs are well tolerated and have high efficacy, liver biopsies
are no longer routinely used to justify the use antiviral ther-
apy following liver transplantation.
Citation of this article: Aby E, Jimenez MA, Grotts JF,
Agopian V, French SW, Busuttil RW, et al. Diminishing use of
liver biopsy among liver transplant recipients for hepatitis C.
J Clin Transl Hepatol 2017;5(3):197–202. doi: 10.14218/
JCTH.2016.00073.
Introduction
Hepatitis C virus (HCV) affects over 3 million individuals in
the United States.1 Patients with HCV, however, are often
unaware of their disease because the majority of acutely
infected patients are asymptomatic.1 HCV is an important
medical concern for our society, as the rate of death from
HCV infections is surpassing the rate of death from human
immunodeficiency virus infections in the United States.2
HCV is currently the leading indication for liver transplanta-
tion in the United States,3 while recurrent HCV post-liver
transplantation is universal and a major cause of allograft
loss and mortality.4 Liver transplantation into an HCV infected
recipient leads to HCV-induced allograft hepatitis in 80% of
recipients at 5 years.5
Historically, the diagnosis and management of HCV
pre- and post-liver transplantation has relied on liver biopsy.
Indications for liver biopsy post-transplant in the past have
included evaluating the disease stage and grade, monitoring
response to therapy, and diagnosis of disease. Liver biopsy,
however, is invasive and associated with bleeding, pain and
infection. A retrospective analysis of percutaneous and trans-
jugular liver biopsies for orthotropic liver transplant patients
in 286 patients showed 3.0% overall incidence of liver biopsy
related infection.6
Liver biopsies are also subject to sampling error. One
study examined chronic HCV patients who received multiple
concurrent liver biopsies and found a difference of at least
one histologic stage in approximately one-third of patients,
suggesting that biopsies do not always provide definitive
results.7 Given the risks of and shortcomings associated
with liver biopsy, new modalities have been developed for
the diagnosis and management of chronic hepatitis and fib-
rosis, including serological tests and imaging studies. Advan-
ces in non-invasive imaging and serologic techniques for the
assessment of fibrosis, as well as the introduction of new
direct-acting antiviral agents (DAAs) for HCV, have changed
the indications for liver biopsy.
Strategies for the treatment of HCV have evolved since the
use of subcutaneous injections of alpha interferons (IFN-a)
in 1986. In 1988, ribavirin was combined with IFN-a for
improved, sustained virologic response (SVR).8 The first
DAAs introduced in 2011 were protease inhibitors, telaprevir
and boceprevir, although these agents required the concom-
itant use of interferon and ribavirin due to viral resistance
associated with monotherapy.9 The approval of additional
DAAs in the fall of 2013, including sofosbuvir and simeprevir,
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as part of interferon-free regimens has changed the land-
scape of HCV treatment. The removal of interferon increases
the number of patients who may be able to tolerate treatment
for HCV given the reduced side effects associated with treat-
ment. Furthermore, DAAs are effective. DAAs have been
shown to have SVR of greater than 90%, shorter and more
tolerable treatment regimens, and high barriers to resist-
ance.10 Of note, there is a decline in SVR in patients with
HCV cirrhosis treated with sofosbuvir and simeprevir that cor-
relates with worsening Child-Pugh score; Child-Pugh cirrhosis
classes A, B and C were associated with an SVR of 87%, 77%
and 67% respectively.11
The aim of this study was to determine how the practice
of liver biopsy is changing given the introduction of DAAs
for the treatment of HCV. The hypothesis of our study was
that over the last 10 years there has been a decreased
incidence of liver biopsies after transplantation for HCV,
especially after the introduction of DAAs.
Methods
A single-center, retrospective analysis was conducted, includ-
ing all liver biopsies performed at the University of California,
Los Angeles (UCLA) Medical Center between January 1, 2006
and October 1, 2015 after liver transplantation for HCV.
Exclusion criteria included patients under the age of 18
at the time of transplant, liver biopsies performed within
30 days of transplant, liver biopsies performed to biopsy a
hepatic mass, patients who died within 12 months of trans-
plantation, and biopsies after a second transplant for liver
failure (Fig. 1). Patients were excluded if they died within
12 months of transplantation, as they would not have an
adequate chance for biopsy post-transplantation. Patients
with liver biopsies after repeat liver transplantation were
excluded, as they were transplanted due to allograft failure.
The timeframe of observation was divided into two dis-
crete periods: “Era 1” defines the time period from January 1,
2006 to November 30, 2013; and “Era 2” includes the time
period from December 1, 2013 until October 1, 2015. Era 2
was defined by the Federal Drug Administration’s approval
of DAAs as part of interferon-free regimens. At UCLA, there
has never been a protocol in place for liver biopsies in HCV-
related liver transplant patients before or after the introduc-
tion of DAAs.
All patients had at least 6 months of follow-up. Data were
obtained by review of the medical charts and the UCLA Liver
Transplant database. Demographic data (age, sex, race/
ethnicity, and body mass index (BMI)), HCV genotype, liver
pathology results and laboratory data were recorded.
Continuous variables are presented as medians with inter-
quartile range, and discrete data are presented as number of
group with percent of group. A Wilcoxon rank sum test was
used to compare continuous data between eras and a Fisher’s
exact or chi-square test was used for discrete data. A Cox
proportional hazards model was fit to analyze time to first
biopsy stratified by era. All tests were two-sided, with a
p-value below 0.05 indicating statistical significance. The R
statistical programming environment was used for all data
analysis (R Core Team; Vienna, Austria).
The study was approved by the UCLA Institutional Review
Board (IRB Study Number: 16-000091).
Fig. 1. Flow chart of patients who met inclusion and exclusion criteria for the study population.
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Results
A total of 576 liver transplants were performed at UCLA from
January 1, 2006 to October 1, 2015 for hepatitis C. A total
of 475 patients were included in our analysis. Ninety-six
patients were excluded because they died within 1 year of
transplant and five were excluded because they had under-
gone their first liver transplant prior to study initiation
(Fig. 1). Table 1 shows baseline characteristics of the overall
cohort, stratified by era. A similar proportion of patients
were male in each era (70.1% in Era 1 vs. 65.7% in Era 2,
p= 0.48). Themedian age (in years) at the time of liver trans-
plant was 57.8 in Era 1 compared to 60.1 in Era 2 (p = 0.055).
There were no statistically significant differences between
eras in the percentage of patients who had concomitant hep-
atitis B virus infection, non-alcoholic steatohepatitis (NASH),
alcoholic liver disease, or hepatocellular carcinoma.
There were no statistically significant differences between
eras in lab values, including international normalized ratio
(INR), total bilirubin, serum creatinine (SCr), platelets, alanine
aminotransferase (ALT), or aspartate aminotransferase (AST)
at the time of transplant (Table 2). No differences in HCV viral
load at the time of transplant were noted between eras
(Table 2). The hepatitis C genotype is not known for half of
the patients in Era 1, whereas the genotype is not known in a
quarter of patients in Era 2. The most common hepatitis
C genotype for patients in both eras is genotype 1.
The number of biopsies performed per year divided by
the number of liver transplant patients remained relatively
steady at 0.25–0.35 from 2006 to 2013, with a decline noted
after 2013 (Fig. 2). There was an increase in the number of
patients biopsied as a proportion of liver transplant patients
in 2007 compared to 2006, 0.28 compared to 0.52. The pro-
portion returned to 2006 levels in the following year and
remained consistent until 2013, ranging from 0.27 to 0.35.
The proportion dropped to below 0.15 after 2013.
In the era before the introduction of DAAs, the percentage
of patients biopsied was significantly higher compared to
the era after the introduction of DAAs (Table 1; 56.1% vs.
26.9%, p < 0.001). The percentage of patients biopsied at
least once within 12 months of liver transplant was 46.4%
in the era prior to the introduction of DAAs compared to
Table 1. Baseline characteristics for patients transplanted for HCV separated by era, January 1, 2006 to October 1, 2015 (n = 475)
Variables Era 1 n Era 2 n p-Value
Age at transplant* 57.8 (20.4–75.3) 408 60.1 (28–75.8) 67 0.055
Sex 0.476
Female 29.9% 122 34.3% 23
Male 70.1% 286 65.7% 44
Race
White 34.3% 140 35.8% 24
Asian 7.8% 32 1.5% 1
Black 6.6% 27 9.0% 6
Hispanic 30.4% 124 49.3% 33
Other 20.8% 85 4.5% 3
BMI* 25.9 (15.3–46.8) 408 27.5 (19.9–47.5) 67 0.055
Hepatitis B Liver disease 0.488
No 96.1% 392 98.5% 66
Yes 3.9% 16 1.5% 1
Alcoholic Liver Disease 0.797
No 93.1% 380 92.5% 62
Yes 6.9% 28 7.5% 5
NASH 0.367
No 98.3% 406 98.5% 66
Yes 0.5% 2 1.5% 1
Hepatocellular carcinoma 0.293
No 49.0% 200 41.8% 28
Yes 51.0% 208 58.2% 39
Patients biopsied <0.001
No 43.9% 179 73.1% 49
Yes 56.1% 229 26.9% 18
Days to first biopsy* 150 (32–3102) 67.5 (35–504) 0.001
*Continuous variables presented as median (range).
Abbreviations: BMI, body mass index; NASH, Non-alcoholic steatohepatitis.
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25.9% of patients after the introduction of DAAs (Table 3).
When comparing the timelines to first biopsy, rates of
biopsy appear similar over the first 100 days post-transplant
between patients in each era (Fig. 3). However, after 100
days, patients in Era 2 received fewer biopsies and this
trend persisted to 365 days post-transplant.
In Era 1, the indication for liver biopsy within the first year
was abnormal liver tests in 89.9% of patients, HCV staging in
8.9% of patients and ‘other’ in 1.2% of patients. In Era 2, the
indication for liver biopsy within the first year was abnormal
liver tests in all patients; there were no biopsies performed to
determine HCV staging.
Discussion
The introduction of DAAs is changing the management of HCV
liver disease pre-and post-liver transplantation and conse-
quently is impacting the use of liver biopsies. We reviewed
the rate of liver biopsies before and after the introduction of
DAAs and found that post-DAA introduction, the percentage
of patients receiving liver biopsies post-transplantation
decreased 2-fold.
Recurrence of HCV post-transplantation is nearly universal
and accounts for over 65% of allograft failures and deaths.4
Eradication of HCV prior to liver transplant is often preferred
to treatment post-transplant, as it significantly reduces
the post-transplant recurrence risk and potentially stabilizes
or improves liver disease. However, the response rates to
DAAs in patients with cirrhosis are reduced and patients
with cirrhosis often require a longer duration of therapy,
which substantially increases cost per cure.
Given that HCV recurrence post-transplantation is perva-
sive, DAAs have greatly improved SVR, and DAAs are better
tolerated than interferon-based therapies, we anticipated
that the use of DAAs would lead to a decline in the use of
liver biopsies, which proved correct. In the era before the
introduction of DAAs, the percentage of patients biopsied was
greater than 50%, compared to the era after the introduction
of DAAs, when only slightly greater than 25% were biopsied.
The data suggest that more patients are receiving pre-
emptive treatment with DAAs instead of undergoing a liver
biopsy to determine treatment. When examining patients
in Era 2, 17 of the 67 patients had undetectable HCV RNA
immediately preceding liver transplantation; thirteen patients
had achieved SVR-12 prior to transplant, while four patients
had undetectable HCV RNA, but had not achieved SVR-12.
The achievement of HCV cure prior to transplantation in more
than 20% of patients treated in Era 2 may be one reason why
Table 2. Laboratory values at the time of liver transplant for patients
transplanted for HCV separated by era, January 1, 2006 to
October 1, 2015 (n = 475)
Era 1 Era 2 p-Value
Genotype
1 146 (35.8%) 40 (59.7%)
2 16 (3.9%) 5 (7.5%)
3 18 (4.4%) 5 (7.5%)
4 13 (3.2%) 1 (1.5%)
6 5 (1.2%) 0 (0%)
Unknown 210 (48.5%) 16 (23.9%)
INR* 1.5 (1–4) 1.6 (1–3.7) 0.559
Total
Bilirubin*
3.9
(0.3–83.4)
2.7
(0.3–59.1)
0.734
SCR* 1.1 (0.2–10.1) 1.1 (0.3–3.3) 0.259
Platelets* 61 (10–319) 55 (13–272) 0.181
AST* 79 (18–12278) 93 (20–3017) 0.119
ALT* 53 (4–7279) 66 (13–1148) 0.227
HCV RNA* 513000
(25–6.9e+08)
206500
(43–6.9e+07)
0.299
*Continuous variables presented as median (range).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase;
INR, international normalized ratio; HCV RNA, hepatitis C virus RNA; SCr, serum
creatinine.
Fig. 2. Number of biopsies per year divided by the number of liver transplant patients from January 1, 2006 to October 1, 2015.
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patients in Era 2 were biopsied at a lower rate than patients
in Era 1. In addition, in Era 1 almost 10% of patients were
undergoing liver biopsy for HCV staging, while no patients in
Era 2 underwent liver biopsy for HCV staging.
Despite the fact that fewer patients are undergoing liver
biopsy post-transplantation, in certain circumstances liver
biopsy continues to provide invaluable information necessary
to guide patient care, including cases of suspected rejection.
We posit that in the era of DAAs many of the patients
undergoing liver biopsy within the first year post-liver trans-
plantation are due to concern for rejection.
In addition to the introduction of DAAs, the management
of HCV post-liver transplantation is changing with the inte-
gration of non-invasive measures of liver fibrosis into clinical
practice. Moving forward, we may even see fewer liver
biopsies because of the availability of these serum-based
markers and imaging-based techniques. FibroSpect II (Prom-
etheus Laboratories Inc.), a non-invasive diagnostic panel,
is one such tool that is readily available at our institution.
FibroSpect II, has been shown to successfully differentiate
severe fibrosis (stages 3–4) from no to mild fibrosis (stages
0–1).12 While serum-based tests, such as FibroSpect II, are
useful to establish either minimal fibrosis or cirrhosis, these
modalities are less helpful with mid-range fibrosis or tracking
progression of fibrosis.13 Although FibroSpect II is available
for evaluation of fibrosis at UCLA, only 22 patients underwent
FibroSpect II during the study period, 2006 to 2015. When
DAAs were approved, guidelines recommended HCV treat-
ment regardless of liver disease severity; at UCLA, laboratory
marker-based modalities, such as FibroSpect II, or imaging
modalities, such as magnetic resonance imaging elastogra-
phy, are typically only performed if there is a suspicion for
cirrhosis.
Our study has a number of limitations that warrant
discussion. First, it is a single center retrospective analysis,
which limits generalizability given the geographic and institu-
tional differences in liver transplantation. Its retrospective
nature and the inherent limitations of an observational design
may result in bias due to several confounding variables,
including unmeasured patient characteristics. For approxi-
mately half of the patients in Era 1 and a quarter of the
patients in Era 2, the genotype was unknown. Genotype is
important in HCV management decisions, given that certain
genotypes, including HCV 1b and 4, are known factors that
predict a poor response to standard anti-viral therapy.14 The
era after the introduction of DAAs has a small sample size,
given the relatively recent development of non-interferon
DAA regimens, and consequently some patients had only
6 months of follow up. However, it is important to recognize
that the vast majority of initial acute rejection episodes occur
within the first 6 months of transplantation.15–17
Table 3. Cumulative percent of liver biopsies performed at 90, 180, 270 and 365 days post-transplantation separated by era, January 1, 2006 to October 1,
2015
Era 1 Era 2
Days from
transplant
Cumulative number
of biopsies
Cumulative percent
biopsied
Cumulative number
of biopsies
Cumulative percent
biopsied p-value
90 69 17.1 11 16.4 >0.99
180 123 31.8 16 24 >0.99
270 148 39.6 16 24 0.138
365 169 46.4 17 25.9 0.033
Fig. 3. Percentage of patients biopsied post-liver transplant for hepatitis C (HCV), separated by era (p = 0.033 at 365 days).
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The results of our single center study demonstrate that use
of the combination of sofosbuvir and simeprevir is efficacious,
safe and tolerable. This combination of DAAs should be
considered in liver transplant recipients with recurrent HCV
who are candidates for antiviral therapy. Further studies are
needed compare the utility of sofosbuvir and simeprevir with
other HCV non-interferon-based therapies.
The results of our study indicate that the introduction of
DAAs is changing the role of liver biopsy post-liver trans-
plantation. Given the substantially improved tolerability, SVR,
and safety of DAAs against HCV, there is increasing interest
in avoiding the potential complications of a liver biopsy.
Thus, patients are more likely to be treated for HCV prior to
transplantation and to be treated for HCV recurrence post-
transplantation without a liver biopsy prior to initiation of
therapy. Further studies are needed to determine if those
who are biopsied less frequently have improved outcomes
compared to those who are biopsied more frequently. Addi-
tional prospective studies are needed to develop algorithms
for the use of liver biopsy in the evaluation and treatment
of HCV recurrence post-liver transplantation and to under-
stand which subgroups of patients with HCV recurrence post-
transplantation may benefit from liver biopsy.
In summary, this study confirmed that increased use of
DAAs has led to a decline in the use of liver biopsies and thus
are changing the management of HCV liver disease post-liver
transplantation.
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